• Something wrong with this record ?

Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors

J. Soukup, M. Manethova, V. Stejskal, H. Hornychova, T. Cesak, D. Netuka, A. Ryska, F. Gabalec

. 2023 ; 34 (3) : 333-341. [pub] 20230808

Language English Country United States

Document type Journal Article

Grant support
LM2023033 BBMRI-CZ
EF16_013/0001674 European Regional Development Fund-Project BBMRI-CZ Biobank network
DIAG Charles University Cooperatio Program
MO 1012 Czech Ministry of Defense

E-resources Online Full text

NLK ProQuest Central from 1997-04-01 to 1 year ago
Medline Complete (EBSCOhost) from 1997-03-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-04-01 to 1 year ago

HoxB13 is a transcription factor involved in defining of posterior endodermal derivatives, including prostate and rectum. While it is used as a marker of prostatic adenocarcinoma, it has not been studied systematically in neuroendocrine neoplasms. Thus, we performed HoxB13 immunohistochemistry in tissue microarrays and the whole sections of 232 neuroendocrine neoplasms. These included 34 paragangliomas (PGs), 20 cauda equina neuroendocrine tumors (CENETs), 123 well-differentiated neuroendocrine tumors (WDNETs), and 55 neuroendocrine carcinomas (NECs). WDNETs were additionally analyzed with SATB2, and colorectal WDNETs with CDX2 and serotonin immunohistochemistry. In total, HoxB13 immunoreactivity was observed in 95% (19/20) CENETs, 10.6% (13/123) WDNETs, and 12.9% (7/54) NECs. No PGs were positive. Large intestine WDNETs expressed HoxB13 in 68.4% (13/19); five negative tumors originated in cecum and one in rectum. In rectum, 92.9% (13/14) WDNETs expressed HoxB13. HoxB13 was 92.9% sensitive and 100% specific, showing 100% positive predictive value for the rectal origin of WDNET. In NECs, HoxB13 was positive in 15.4% (2/13) GIT tumors and 80% (4/5) prostatic NECs, but in none of urinary bladder NECs (0/8). SATB2 was positive in 17.1% (21/123) WDNETs, including 78.9% (15/19) of colorectal WDNETs, 71.4% (5/7) appendiceal WDNETs, and 2.9% (1/34) small intestine WDNETs. All 4 SATB2-negative large bowel tumors originated in the cecum. When both markers combined, HoxB13+/SATB2+ immunoprofile was seen exclusively in rectal WDNETs (positive predictive value 100%), while HoxB13-/SATB2+ immunoprofile was highly suggestive of the appendiceal origin (positive predictive value 71.4%). Therefore, HoxB13 can be useful as an immunohistochemical marker of rectal WDNETs and prostatic NECs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016330
003      
CZ-PrNML
005      
20231026110027.0
007      
ta
008      
231013s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12022-023-09779-9 $2 doi
035    __
$a (PubMed)37552455
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Soukup, Jiri $u Department of Pathology, Military University Hospital Prague, Prague, Czech Republic. 2jiri.soukup@gmail.com $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, Prague, 500 05, Czech Republic. 2jiri.soukup@gmail.com
245    10
$a Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors / $c J. Soukup, M. Manethova, V. Stejskal, H. Hornychova, T. Cesak, D. Netuka, A. Ryska, F. Gabalec
520    9_
$a HoxB13 is a transcription factor involved in defining of posterior endodermal derivatives, including prostate and rectum. While it is used as a marker of prostatic adenocarcinoma, it has not been studied systematically in neuroendocrine neoplasms. Thus, we performed HoxB13 immunohistochemistry in tissue microarrays and the whole sections of 232 neuroendocrine neoplasms. These included 34 paragangliomas (PGs), 20 cauda equina neuroendocrine tumors (CENETs), 123 well-differentiated neuroendocrine tumors (WDNETs), and 55 neuroendocrine carcinomas (NECs). WDNETs were additionally analyzed with SATB2, and colorectal WDNETs with CDX2 and serotonin immunohistochemistry. In total, HoxB13 immunoreactivity was observed in 95% (19/20) CENETs, 10.6% (13/123) WDNETs, and 12.9% (7/54) NECs. No PGs were positive. Large intestine WDNETs expressed HoxB13 in 68.4% (13/19); five negative tumors originated in cecum and one in rectum. In rectum, 92.9% (13/14) WDNETs expressed HoxB13. HoxB13 was 92.9% sensitive and 100% specific, showing 100% positive predictive value for the rectal origin of WDNET. In NECs, HoxB13 was positive in 15.4% (2/13) GIT tumors and 80% (4/5) prostatic NECs, but in none of urinary bladder NECs (0/8). SATB2 was positive in 17.1% (21/123) WDNETs, including 78.9% (15/19) of colorectal WDNETs, 71.4% (5/7) appendiceal WDNETs, and 2.9% (1/34) small intestine WDNETs. All 4 SATB2-negative large bowel tumors originated in the cecum. When both markers combined, HoxB13+/SATB2+ immunoprofile was seen exclusively in rectal WDNETs (positive predictive value 100%), while HoxB13-/SATB2+ immunoprofile was highly suggestive of the appendiceal origin (positive predictive value 71.4%). Therefore, HoxB13 can be useful as an immunohistochemical marker of rectal WDNETs and prostatic NECs.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a neuroendokrinní nádory $x diagnóza $x patologie $7 D018358
650    _2
$a nádorové biomarkery $7 D014408
650    _2
$a transkripční faktory $7 D014157
650    12
$a nádory rekta $x diagnóza $x patologie $7 D012004
650    12
$a kolorektální nádory $7 D015179
650    12
$a neuroendokrinní karcinom $x diagnóza $7 D018278
650    12
$a nádory močového měchýře $7 D001749
650    _2
$a homeodoménové proteiny $7 D018398
655    _2
$a časopisecké články $7 D016428
700    1_
$a Manethova, Monika $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, Prague, 500 05, Czech Republic
700    1_
$a Stejskal, Vaclav $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, Prague, 500 05, Czech Republic
700    1_
$a Hornychova, Helena $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, Prague, 500 05, Czech Republic
700    1_
$a Cesak, Tomas $u Department of Neurosurgery, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Prague, Czech Republic
700    1_
$a Netuka, David $u Department of Neurosurgery and Neurooncology, 1st Medical Faculty, Military University Hospital Prague, Charles University, Prague, Czech Republic
700    1_
$a Ryska, Ales $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolska 581, Prague, 500 05, Czech Republic
700    1_
$a Gabalec, Filip $u 4th Department of Internal Medicine, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Prague, Czech Republic
773    0_
$w MED00001517 $t Endocrine pathology $x 1559-0097 $g Roč. 34, č. 3 (2023), s. 333-341
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37552455 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026110021 $b ABA008
999    __
$a ok $b bmc $g 2000066 $s 1202692
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 34 $c 3 $d 333-341 $e 20230808 $i 1559-0097 $m Endocrine pathology $n Endocr Pathol $x MED00001517
GRA    __
$a LM2023033 $p BBMRI-CZ
GRA    __
$a EF16_013/0001674 $p European Regional Development Fund-Project BBMRI-CZ Biobank network
GRA    __
$a DIAG $p Charles University Cooperatio Program
GRA    __
$a MO 1012 $p Czech Ministry of Defense
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...